Transgenomic (TBIO) Reports Q4 Loss of $0.77/Share

Transgenomic (NASDAQ: TBIO) reported Q4 EPS of ($0.77), versus ($0.57) reported last year. Revenue for the quarter came in at $7.7 million, versus $6.2 million reported last year.

For earnings history and earnings-related data on Transgenomic (TBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c